Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Indisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 3/20 | 0.54 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.54 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.49 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.49 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indisetron SCHEMBL2229963 | 1.00 | NPC1 (0.60) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL15313306 | 1.00 | NPC1 (0.60) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL18311525 | 0.99 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL29398028 | 0.99 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL332330 | 0.99 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL1073375 | 0.99 | NPC1 (0.61) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| Indisetron SCHEMBL1649312 | 0.97 | NPC1 (0.59) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| SCHEMBL2086084 | 0.90 | NPC1 (0.67) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| SCHEMBL7336988 | 0.89 | NPC1 (0.58) | NPC1RAB9AUSP30DYRK1AGSK3B | |
| SCHEMBL7336990 | 0.89 | NPC1 (0.58) | NPC1RAB9AUSP30DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503764-B1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2010-01-06 | — | — | EP | claimed |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250188103-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250177362-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20090169545-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2009-07-02 | — | — | US | disclosed |
| US-20080125360-A1 | Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders | NILSSON HENRIK | 2008-05-29 | — | — | US | disclosed |
| US-20060094715-A1 | 5-Ht4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2006-05-04 | — | — | US | disclosed |
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-0851756-B1 | USE OF ONDANSETRON IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TREMOR | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | EP | disclosed |
| EP-1239882-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-0851756-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997010823-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | CHRNA7 118/4885HTR3A 1767/4885HTR3E 1457/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | CHRNA7 118/4885HTR3A 1767/4885HTR3E 1457/4885 |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA3, ADORA2A | CHRNA7 234/4885HTR3A 6/4885HTR3E 34/4885 |
| US-20250188103-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CHRNA7 1641/4885HTR3A 104/4885HTR3E 134/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | CHRNA7 1523/4885HTR3A 170/4885HTR3E 189/4885 |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | CHRNA7 579/4885HTR3A 246/4885HTR3E 164/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | CHRNA7 2598/4885HTR3A 386/4885HTR3E 530/4885 |
| US-20250177362-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | CHRNA7 1523/4885HTR3A 170/4885HTR3E 189/4885 |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GLP1R, IAPP, GPR119 | CHRNA7 1087/4885HTR3A 851/4885HTR3E 471/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CHRNA7 74/4885HTR3A 309/4885HTR3E 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.